ASCO 2017 Renal Cancer

Viewing 1-20 of 44 articles

ASCO 2017: Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients

ASCO 2017: Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT)

ASCO 2017: Can Subgroup Analyses Identify Enrichment Strategies for Adjuvant RCC Studies?

ASCO 2017: Emerging VEGF-I/O Combinations: Efficacy and Toxicity

ASCO 2017: A phase I/II study to assess the safety and efficacy of pazopanib and pembrolizumab in patients with advanced renal cell carcinoma

ASCO 2017: Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer

ASCO 2017: Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab in cisplatin-ineligible advanced urothelial cancer

ASCO 2017: Integrative analysis of sarcomatoid clear-cell renal cell carcinomas reveals an immune subgroup

ASCO 2017: IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma patients of atezolizumab and bevacizumab vs and following atezo or sunitinib

ASCO 2017: First-line avelumab + axitinib therapy in patients with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial

ASCO 2017: Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression

ASCO 2017: Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in patients with advanced renal cell carcinoma

ASCO 2017: TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents

ASCO 2017: A phase III study of atezolizumab vs placebo as adjuvant therapy in renal cell carcinoma patients at high risk of recurrence following resection (IMmotion010)

ASCO 2017: Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC)

ASCO 2017: A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC)

ASCO 2017: A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC)

ASCO 2017: Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101)

ASCO 2017: Inter and intra-tumor heterogeneity of PD-L1 and MET expression in metastatic renal cell carcinoma

ASCO 2017: The Dynamic Landscape of Renal Cell Carcinoma Biomarkers: Can We Predict Prognosis, Treatment Response, and Outcome?

1
2
3